Stijn Van Rompay

Stijn van Rompay currently serves as the CEO and reference shareholder of Hyloris Pharmaceuticals, a Belgian specialty biopharma company focused on reinventing existing medications, since 2014. Stijn is also a board member and reference shareholder of the PE Group, which specializes in private equity investments and corporate finance in the Belux region. Additional roles include chairman of Exo Biologics and a previous membership on the board of IMCYSE, which develops immune therapies for various diseases. Stijn held leadership positions at Alter Pharma and Uteron Pharma, focusing on niche pharmaceuticals and female healthcare products, and has extensive experience in the pharmaceutical industry through previous roles at Docpharma and BBL-ING. Stijn holds a Master’s in Economics from the University of Antwerp.